Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705684 | 1.00 | MAOB (0.46) | MAOBEGFRCYP1A2GAAMAPT | |
| SCHEMBL5352721 | 0.98 | MAOB (0.44) | MAOBEGFRCYP1A2GAAMAPT | |
| SCHEMBL3901324 | 0.84 | LMNA (0.38) | MAOBCYP1A2GAAMAPTALDH1A1 | |
| SCHEMBL11138464 | 0.83 | MAOB (0.43) | MAOBEGFRCYP1A2GAAMAPT | |
| SCHEMBL232409 | 0.82 | CA12 (0.45) | MAOBEGFRCYP1A2GAAMAPT | |
| SCHEMBL3702205 | 0.80 | MAOB (0.44) | MAOBEGFRCYP1A2GAAMAPT | |
| SCHEMBL4576483 | 0.80 | CA12 (0.44) | MAOBEGFRCYP1A2GAAMAPT | |
| SCHEMBL8414445 | 0.78 | MAOB (0.46) | MAOBEGFRCYP1A2GAAMAPT | |
| SCHEMBL1877066 | 0.78 | MAOB (0.42) | MAOBEGFRCYP1A2GAAMAPT | |
| SCHEMBL8171076 | 0.77 | NCEH1 (0.47) | CYP1A2MAPTALDH1A1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119186651-A | Catalyst for preparing dialkyl carbonate and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| CN-119186651-A | Catalyst for preparing dialkyl carbonate and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-12-01 | — | — | US | disclosed |
| EP-4038052-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114555573-A | Prostaglandin E2(PGE2)EP4Receptor antagonists | 多曼治疗学公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021064189-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-04-08 | — | — | WO | disclosed |
| US-7655653-B2 | Tetrahydrobenzfluorene derivatives | N.V. ORGANON (NL) | 2010-02-02 | — | — | US | disclosed |
| US-20080058361-A1 | TETRAHYDROBENZFLUORENE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-06 | — | — | US | disclosed |
| US-5306604-A | Dispersibility, low melting points | EASTMAN KODAK COMPANY (US) | 1994-04-26 | — | — | US | disclosed |
| EP-0185030-B1 | BILEVEL RESIST | AT&T Corp. (US) | 1988-11-02 | — | — | EP | disclosed |
| US-4675370-A | Resin systems derived from benzocyclobutene-alkyne imide monomers | UNIVERSITY OF DAYTON (US) | 1987-06-23 | — | — | US | disclosed |
| EP-0185030-A1 | — | AMERICAN TELEPHONE & TELEGRAPH | 1986-06-25 | — | — | EP | disclosed |
| WO-1985005470-A1 | BILEVEL RESIST | AMERICAN TELEPHONE & TELEGRAPH COMPANY (US) | 1985-12-05 | — | — | WO | disclosed |
| US-4521274-A | Bilevel resist | AT&T BELL LABORATORIES (US) | 1985-06-04 | — | — | US | disclosed |
| US-4500628-A | IRRADIATING FILM CONSISTING OF POLYMER AND ORGANOSILICON MONOMER | AT&T BELL LABORATORIES (US) | 1985-02-19 | — | — | US | disclosed |
| US-4396704-A | Solid state devices produced by organometallic plasma developed resists | BELL TELEPHONE LABORATORIES, INCORPORATED (US) | 1983-08-02 | — | — | US | disclosed |
| US-3992536-A | SEDATIVES AND MUSCLE RELAXANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-11-16 | — | — | US | disclosed |
| US-3931185-A | SEDATIVES, MUSCLE RELAXANT | BOEHRINGER INGELHEIM GMBH (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058361-A1 | TETRAHYDROBENZFLUORENE DERIVATIVES | ESR1, ESR2, GPER1 | MAOB 889/4885EGFR 79/4885CYP1A2 69/4885 |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | MAOB 2612/4885EGFR 485/4885CYP1A2 864/4885 |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER2 | MAOB 3127/4885EGFR 507/4885CYP1A2 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.